Final Thoughts on JAK Inhibitor for AD

EP: 1.JAK Inhibitor Overview and Relevance to AD

EP: 2.Comparing Current Treatment Agents for AD

EP: 3.Clinical Experience With JAK Inhibitor in AD

EP: 4.Experts Present Background on Long-Term Safety Study of Upadacitinib for AD

EP: 5.Experts on Results of Long-Term Safety Study of Upadacitinib for AD

EP: 6.Conclusions of Study on Long-Term Safety Study of Upadacitinib for AD

EP: 7.Assessing Risk Factors of Oral JAK Inhibitors and Traditional Agents

EP: 8.Experts Present Background on JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP: 9.Experts on Results of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP: 10.Visualizing Safety Rates: Drug Events, Disease Baseline, and General Population Baseline

EP: 11.Box Warning and JAK Inhibitor

EP: 12.JAK Inhibitor Selectivity

EP: 13.Conclusions of JAK Inhibitor vs Systemic Immunosuppressant Safety Study

EP: 14.Evolving the Standard of Care for AD: Safety and Treatment Response

EP: 15.Transitioning Patients from Traditional Immunosuppressive Agents to JAK Inhibitor

EP: 16.AD Endotypes and Outcomes

Now Viewing

EP: 17.Final Thoughts on JAK Inhibitor for AD

Christopher Bunick, MD, PhD

Associate Professor, Dermatologist

Yale University

Middlebury, Connecticut

Ruth Ann Vleugels, MD, MPD, MBA

Vice-Chair of Academic Affairs

Department of Dermatology at Brigham and Women’s Hospital

Boston, Massachusetts

Program Description: Experts discuss the results of multiple studies analyzing the incident rates and safety of Janus Kinase (JAK) inhibitors in the treatment of atopic dermatitis (AD).

Segment Description: Experts conclude their discussion highlighting key takeaways and considerations when using Janus Kinase (JAK) inhibitors as treatment for atopic dermatitis (AD).